ENDRA Life Sciences' mission is to bring new capabilities to ultrasound and broaden access to better healthcare.
ENDRA is developing a next generation Thermo-Acoustic Enhanced UltraSound (TAEUS™) system to enable clinicians to visualize human tissue composition, function and temperature in ways previously possible only with CT & MRI -- at a fraction of the cost, and at the point-of-care.
ENDRA's first TAEUS application will focus on the quantification of fat in the liver, for early detection and monitoring of Non-Alcoholic Fatty Liver Disease, which affects over 1 billion people globally.
|May 14, 2020||ENDRA Life Sciences Provides Business Update and Reports First Quarter 2020 Financial Results|
|May 06, 2020||ENDRA Life Sciences Strengthens IP Portfolio with Issuance of Additional Patents for its Innovative Fatty Liver Imaging Probe|
|May 01, 2020||ENDRA Life Sciences to Host First Quarter 2020 Financial Results Conference Call and Webcast on Thursday, May 14, 2020 at 4:30 p.m. ET|
|Apr 30, 2020||ENDRA Life Sciences Builds on CE Mark Approval|
|Apr 13, 2020||ENDRA Life Sciences Announces Cash Strategy and Business Update in Response to COVID-19|
|Day Range||0.8705 - 0.9651|
|52 Week Range||0.5990 - 2.2500|
|Bid/Ask||0.8869 / 0.8935|
|Bid/Ask Size||200 X 700|
|Market Cap||12.96 million|
|Shares Outstanding||14.5 million|
|Dividend/Yield||0.0000 / 0.0000%|
|P/E Ratio (TTM)||N/A|